AstraZeneca aims to advance clinical practice in CV risk management with new data at ACC 2018
10 abstracts including three late breakers presenting new Phase III data and landmark real-world evidence from Asia, Middle East and North America
Ämnen: Industri, tillverkning
-
-
MedImmune to create stand-alone company for early-stage inflammation and autoimmunity biologics
AstraZeneca today announced that its global biologics research and development arm, MedImmune, is spinning out six molecules fromits early-stage inflammation and autoimmunity programmes into an independent biotech company, Viela Bio.
-
Lynparza receives positive EU CHMP opinion in platinum-sensitive relapsed ovarian cancer
AstraZeneca and MSD’s new Lynparza tablet formulation recommended for maintenance therapy regardless of BRCA status
-
US FDA approves Imfinzi for unresectable Stage III non-small cell lung cancer
Imfinzi is the only immunotherapy approved for patients with unresectable Stage III non-small cell lung cancer Imfinzi showed an 11.2 month improvement in median progression-free survival (16.8 months compared to 5.6 months on placebo)
-
Selumetinib granted Orphan Drug Designation by the US FDA for neurofibromatosis type 1
AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1).
-
Brilinta significantly reduces CV events and coronary death beyond one year in heart attack survivors with multi-vessel disease
Study reveals prolonging treatment with Brilinta 60mg after one year, reduces risk of major adverse cardiac events (MACE) by 19% and coronary death by 36%1 Builds on analysis2 showing 5-year ischaemic risk post-heart attack and benefits of long-term cardiovascular (CV) protection with Brilinta 60mg
-
AstraZeneca PLC:s resultatrapport för helåret och fjärde kvartalet 2017
Positiv utveckling avseende kommersiellt genomförande och kostnadsdisciplin; produktförsäljningen ökade under kvartalet. AstraZeneca står inför tillväxt i produktförsäljningen för helåret 2018
-
AstraZeneca reports top-line phase III KRONOS trial results for PT010 triple combination therapy in chronic obstructive pulmonary disease
AstraZeneca today announced top-line results from the Phase III KRONOS trial that showed PT010 (budesonide/glycopyrronium/formoterol fumarate 320/14.4/9.6µg, using Aerosphere Delivery Technology, in a pressurised metered-dose inhaler or pMDI) demonstrated a statistically significant improvement compared with dual combination therapies in six out of seven lung function primary endpoints.
-
AstraZeneca listed as one of the world's Top-100 most sustainable companies and recognised for its three-fold increase in renewable energy usage
AstraZeneca ranked 34th in Corporate Knights’ 14th annual Global 100 list of the most sustainable companies in the world
AstraZeneca identified as “biggest achiever” alongside Bank of America, and Coca Cola Enterprises Inc. (now Coca Cola European Partners) for 300% increase in renewable electricity in a single year
AstraZeneca has been recognised for its commitment to sustainability with tw -
Lynparza receives approval in Japan for the treatment of advanced ovarian cancer
Lynparza is the first PARP inhibitor approved in Japan
Lynparza tablets approved as maintenance treatment for women with platinum-sensitive relapsed ovarian cancer regardless of BRCA mutation status
AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the Japanese Ministry of Health, Labour and Welfare has approved Lynparza -
Fasenra receives approval in Japan
Approval based on Phase III WINDWARD programme that demonstrated significant reductions in asthma exacerbations, improvements in lung functionand reductions inoral corticosteroid use from baseline, versus placebo
Fasenra is the first approved respiratory biologic with an 8-week maintenance dosing schedule
AstraZeneca and its global biologics research and development arm, MedImmune, today ann -
Risk of repeat heart attack twice as likely from occlusions in arteries that did not cause initial event
AstraZeneca announced today the publication of a new analysis from an ongoing real-world quality registry that suggests the risk of experiencing a repeat heart attack (also known as a myocardial infarction or MI) from occlusions in non-stentedarteries is twice as high as the risk stemming from the initially stented artery following a first heart attack.
-
Lynparza approved by US FDA in germline BRCA-mutated metastatic breast cancer
AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has approved Lynparza (olaparib), for use in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm),
-
Fasenra receives EU approval for severe eosinophilic asthma
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the European Commission (EC) has approved Fasenra (benralizumab) as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting beta-agonists.
-
US FDA accepts regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer
Acceptance follows FDA Breakthrough Therapy Designation
Tagrisso granted Priority Review
AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for the use of Tagrisso (osimertinib), a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with clinical activity agains -
AstraZeneca to highlight its commitment to blood cancers at the 2017 American Society of Hematology Annual Meeting
AstraZeneca, along with Acerta Pharma, its haematology research and development centre of excellence, and MedImmune, its global biologics research and development arm, will highlight significant progress in blood cancer research at the 59th 2017 American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA
-
Tudorza reduces exacerbations and demonstrates cardiovascular safety in COPD patients
AstraZeneca today announced positive top-line results of the Phase IV ASCENT trial for Tudorza Pressair (aclidinium bromide 400 μg, twice-daily), a long-acting muscarinic antagonist (LAMA), in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), with a history of cardiovascular disease and/or significant cardiovascular risk factors.
-
The European Medicines Agency accepts regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer
AstraZeneca today announced that the European Medicines Agency has accepted a variation to the Marketing Authorisation Application (MAAv) for Tagrisso (osimertinib),
-
AstraZeneca and Chinese Future Industry Investment Fund establish joint venture to develop new medicines in China
AstraZeneca today announced a strategic joint venture with the Chinese Future Industry Investment Fund (FIIF) to form an equally-owned, stand-alone company in China to discover, develop and commercialise potential new medicines to help meet unmet needs globally, and to bring innovative new medicines to patients in China faster.
-
AstraZeneca makes regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer in Japan
AstraZeneca today announced the submission of a supplemental new drug application (sNDA) to Japan’s Pharmaceuticals and Medical Devices Agency for the use of Tagrisso (osimertinib).
Visa mer
Loading...